These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29198865)

  • 1. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
    Culhane JC; Wang D; Yen PM; Cole PA
    J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
    Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
    Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
    Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
    J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
    Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
    Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
    Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
    ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide.
    Kakizawa T; Mizukami T; Itoh Y; Hasegawa M; Sasaki R; Suzuki T
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1193-5. PubMed ID: 26794039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
    Schmidt DM; McCafferty DG
    Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
    Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
    Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human histone demethylase LSD1 reads the histone code.
    Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
    J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
    Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.
    Metzger E; Imhof A; Patel D; Kahl P; Hoffmeyer K; Friedrichs N; Müller JM; Greschik H; Kirfel J; Ji S; Kunowska N; Beisenherz-Huss C; Günther T; Buettner R; Schüle R
    Nature; 2010 Apr; 464(7289):792-6. PubMed ID: 20228790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.